Europe — EMA
Nuwiq (Simoctocog Alfa)
Simoctocog alfa, the active ingredient in Nuwiq, is a Factor VIII replacement therapy presented as a sterile solution for intravenous use. It is used to treat and prevent bleeding episodes in patients with hemophilia A.
Request sourcing
What is Simoctocog Alfa?
Simoctocog alfa, the active ingredient in Nuwiq, is a Factor VIII replacement therapy presented as a sterile solution for intravenous use. It is used to treat and prevent bleeding episodes in patients with hemophilia A. GNH USA supplies Nuwiq as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Nuwiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Simoctocog Alfa used for?
Nuwiq acts ...
What are the side effects of Simoctocog Alfa?
Common
What precautions apply to Simoctocog Alfa?
Precautions
What does Simoctocog Alfa interact with?
Major
